Vienna-based biotechnology company Delta4 has secured European patents for two compounds that show significant potential in treating focal segmental glomerulosclerosis (FSGS), a rare and serious kidney disease. The breakthrough, achieved through the company's AI-driven platform Hyper-C, represents a promising advancement in addressing a complex medical condition with limited current treatment options.
The first patented compound, clopidogrel, is an existing cardiovascular medication that demonstrated remarkable results in animal studies. Research revealed a 61% reduction in urinary albumin to creatinine ratio and a 67.9% reduction in kidney damage scores. The drug exhibited anti-inflammatory, anti-fibrotic, and immune-modulating properties crucial for managing FSGS progression.
The second breakthrough involves a novel combination of saroglitazar and myristic acid, which showed significant improvements in kidney pathology. The combination exhibited reduced proteinuria, decreased glomerular sclerosis, and synergistic therapeutic effects targeting multiple disease mechanisms.
Delta4's Hyper-C platform leverages advanced computational biology to analyze extensive biomedical datasets, identifying subtle molecular relationships between diseases and potential treatments. This approach enables the company to predict therapeutic efficacy and mechanisms of action with unprecedented accuracy.
CEO Kurt Herpel emphasized the significance of these patents, highlighting the potential to provide new therapeutic options for patients suffering from this challenging kidney disease. The company plans to advance these compounds into clinical trials, aiming to validate the promising results observed in preclinical studies.
The development underscores the emerging role of artificial intelligence in pharmaceutical research, demonstrating how machine learning can accelerate drug discovery and potentially bring innovative treatments to market more efficiently.
